This site is intended for US healthcare professionals responsible for population-based decision making at hospitals and US oncology practices.
Elements of an ongoing MPN quality program may include:
Tracking symptoms (MPN-SAF TSS/MPN-10)
Determining risk stratification category
Monitoring lab values and blood counts
Assessing the spleen
Optimizing dosing
Use the resources and videos found on this site if you are ready to take a proactive approach to developing quality programs for your patients living with MPNs.
Robyn Scherber, MD, MPH, is Sr. Director, Medical Affairs at Incyte. Additionally, she is an Assistant Professor of Medicine at the University of Texas Health Science Center at San Antonio. She provides a physician perspective on the importance of quality initiatives for patients with MPNs and discusses assessing symptom burden, conducting spleen assessments, and addressing patient needs concretely and realistically.
John Winters, MD, Staff Physician at New England Cancer Specialists, offers a physician's perspective on the practical application of quality initiatives and the importance of regular symptom tracking and assessment for patients with MPNs.
Kellie Mozingo, RN, Practice Manager at Hunterdon Hematology Oncology, provides her perspective on the importance of quality initiatives for patients with MPNs, along with tips for implementing an MPN quality initiative in an oncology practice.
Michael Reff, RPh, MBA, Founder and Executive Director of the National Community Oncology Dispensing Association (NCODA), explains the need for practices and pharmacists to learn about rare cancers so they are better prepared to provide quality patient care. Watch as he discusses the importance of quality initiatives for patients with myeloproliferative neoplasms (MPNs).
Julianne Orr Darling, PharmD, BCOP, an Oncology and Clinical Pharmacist at Indiana University Health, talks about how risk stratification is an important part of managing patients with MF. Review risk stratification criteria and how pharmacists can create a list of patients for a potential quality initiative. Learn more by watching this video (a downloadable brochure about MF risk is available below as a PDF).
Neal Dave, PharmD, Pharmacy Area Manager, Texas Oncology, talks about PV as a hematologic malignancy that may become advanced in a subset of patients despite treatment with hydroxyurea and phlebotomy, resulting in ineffective disease control.3-6 For more information about PV and quality interventions, watch this PV walkthrough (available for download below as a PDF).
Neal Dave, PharmD at Texas Oncology, describes the steps his team uses to work with patients and medical personnel with the goal of improving patient outcomes. Explore a multidisciplinary approach that pharmacists can take to implement a quality initiative for patients with PV. View the video.
Kelly Mozingo, RN, Practice Manager at Hunterdon Hematology Oncology teaches you concrete quality initiative goals and implementation strategies.
Dr John Winters gives his opinion about the importance of regular symptom assessment and tracking when developing quality initiatives for patients with MPNs.
Use this downloadable brochure as a resource when implementing a quality intervention for PV.
This brochure provides information that may help you identify and evaluate risk profiles among your patients with MF. This downloadable resource offers insight into strategies for assessing and monitoring risk.
View a guide for pharmacy directors and clinical pharmacists that can help clinicians identify patients with burdensome symptoms of MPNs.
You play an important role in helping to build quality programs for patients living with MPNs. This presentation is intended for US healthcare professionals responsible for population-based decision making at hospitals and US oncology practices.
1. Hewitt M, Simone JV. Ensuring Quality Cancer Care. Washington, DC: National Academy Press, 1999. 2. Neuss MN, Desch CE, McNiff KK, et al. A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. J Clin Oncol. 2005;23(25):6233-6239. 3. Parasuraman S, DiBonaventura M, Reith K, Naim A, Concialdi K, Sarlis NJ. Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. Exp Hematol Oncol. 2016;5:3. 4. Mascarenhas J. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2016;16 suppl:S124-S129. 5. Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680-692. 6. Spivak JL, Considine M, Williams DM, et al. Two clinical phenotypes in polycythemia vera. N Engl J Med. 2014;371(9):808-817.
The website and the information contained or referenced on the website is intended for informational purposes only. You may not copy, transfer, reproduce, modify, or create derivative works of any part of this content for any reason and may not use this content for any commercial purpose without the express written permission of Incyte. The website does not provide medical or professional services or advice and should not be relied upon as the basis of any healthcare decision. Persons requiring diagnosis or treatment or with questions specific to an individual are urged to contact their healthcare provider. The information on this website has not been supported or endorsed by any entity for reimbursement or accreditation purposes. Incyte makes no representations or warranties and explicitly disclaims the appropriateness or applicability of this content to any specific patient's care or treatment. Any clinician seeking to treat a patient using this content is expected to use independent medical judgment in the context of individual clinical circumstances of a specific patient's care or treatment. INCYTE MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE ACCURACY, COMPLETENESS OR SUITABILITY OF THE INFORMATION MADE AVAILABLE ON THE WEBSITE. Incyte disclaims any and all liability related to use of the website or any website linked to this notice.
If you have any questions or would like to request a National Account Manager discussion, please click here.
